United States v. Shinderman

232 F.R.D. 147, 2005 U.S. Dist. LEXIS 25613, 2005 WL 2847379
CourtDistrict Court, D. Maine
DecidedOctober 27, 2005
DocketNo. CRIM 05-67P-H
StatusPublished
Cited by4 cases

This text of 232 F.R.D. 147 (United States v. Shinderman) is published on Counsel Stack Legal Research, covering District Court, D. Maine primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Shinderman, 232 F.R.D. 147, 2005 U.S. Dist. LEXIS 25613, 2005 WL 2847379 (D. Me. 2005).

Opinion

MEMORANDUM DECISION ON MOTION FOR EARLY PRODUCTION OF DOCUMENTS

DAVID M. COHEN, United States Magistrate Judge.

The defendant, Mare Shinderman, M.D., requests court approval of subpoenas to be issued to six entities for information to be used in a planned motion to dismiss based, inter alia, on

equitable estoppel on account of governmental confusion, equitable estoppel on account of affirmative government misconduct, equitable estoppel by entrapment, equitable estoppel by public authority, equitable estoppel by governmental silence when it had a duty to act and related bars to criminal prosecution based upon government conduct____

Dr. Shinderman’s Motion for Early Production of Documents as a Precursor to a Motion to Dismiss, etc. (“Motion”) (Docket No. 11) at 11, 15-16. The defendant is charged with 25 counts of using a DEA registration number issued to another person to write a prescription for a controlled substance, 25 counts of issuing an invalid prescription for a controlled substance by forging another person’s name and using that person’s DEA registration number, two counts of furnishing false material information in a pharmacy record or document and 16 counts of making materially false writings and documents in connection with the delivery of health care benefits and services. Indictment (Docket No. 1).

The defendant first requests a subpoena directed to the United States Drug Enforcement Agency for (i) “[a]ll documentation ... associated with any application for registration made” by the defendant in 2001 or 2002 “using a proposed business address of One Delta Drive, Suite A, Westbrook, ME 04092;” (ii) “[a]ll documentation ... concerning the registration or other licensing of CAP Quality Care as an opioid or narcotic treatment program;” (iii) “[a]ll documentation ... concerning DEA policy, regulations, or practices, about the issuance of ... DEA registration numbers to practitioners;” (iv) “[a]ll documentation ... created or obtained by DEA ... concerning any contacts between any DEA official and a member of the news media regarding CAP Quality Care or Dr. Shinderman during the period August 1, 2001, through the present;” (v) “[a]ll documentation ... created or obtained by DEA ... concerning any operational or raid planning associated with the execution of the search warrant that occurred at CAP Quality Care ... on September 9, 2005[sic];” (vi) “[a]ll documentation ... created or obtained by DEA ... concerning any strategic planning that it or its agents may have undertaken with regard to the investigation of CAP Quality Care or Dr. Shinderman;” (vii) “[a]ll documentation created or obtained by DEA ... concerning DEA policy, practice or procedures, or statutory authority, or regulatory authority, concerning the treatment of a practitioner, in general and Dr. Shinderman in particular, who ... prescribes controlled substances for a legitimate medical purpose at a second location for which the practitioner’s DEA registration application is pending approval; or ... prescribes the sort of controlled substances for which he is authorized to prescribed at the location where he is registered;” and (viii) “[a]ll information contained in any ... database that DEA used [sic] to store ‘derogatory1 information about individuals, including practitioners.” Attachment “A” to Motion at [l]-[3] (emphasis in original).

The parties agree that the defendant’s requests are governed by Fed.R.Crim.P. 17(c). Motion at 1; Government’s Memorandum of Law in Response to Defendant’s Motion for Rule 17 Subpoenas (“Opposition”) (Docket No. 15) at 1. That rule provides, in relevant part:

(c) Producing Documents and Objects.
(1) In General. A subpoena may order the witness to produce any books, papers, documents, data, or other objects the subpoena designates. The court may direct the witness to produce the designated items in court before trial or before that are to be offered in evidence. When the [150]*150items arrive, the court may permit the parties and their attorneys to inspect all or part of them.

Fed.R.Crim.P. 17(c)(1). The rule also provides that “[n]o party may subpoena a statement of a witness or of a prospective witness under this rule. Rule 26.2 governs the production of the statement.” Fed.R.Crim.P. 17(h). The extremely broad language of the defendant’s request may reasonably be interpreted to include statements of prospective witnesses, in violation of Rule 17(h). If the motion were granted, therefore, the approval would be narrowly drawn to exclude such statements.

In order to obtain production of materials before trial under Rule 17(c), a defendant must show

(1) that the documents are evidentiary and relevant; (2) that they are not otherwise procurable reasonably in advance of trial by exercise of due diligence; (3) that the party cannot properly prepare for trial without such production and inspection in advance of trial and that the failure to obtain such inspection may tend unreasonably to delay the trial; and (4) that the application is made in good faith and is not intended as a general “fishing expedition.”

United States v. Nixon, 418 U.S. 683, 699-700, 94 S.Ct. 3090, 41 L.Ed.2d 1039 (1974); see also United States v. LaRouche Campaign, 841 F.2d 1176, 1179 (1st Cir.1988). “[I]t has always been clear that Rule 17(c) was not intended as a discovery device .... ” 2 C. Wright, Federal Practice & Procedure § 274 at 242 (3d ed.2000); see Bowman Dairy Co. v. United States, 341 U.S. 214, 220, 71 S.Ct. 675, 95 L.Ed. 879 (1951). The burden is on the party seeking the subpoena “to show the evidentiary nature of the requested materials with appropriate specificity.” United States v. Skeddle, 178 F.R.D. 167, 168 (N.D.Ohio 1996). The requesting party “must do more than speculate about the relevancy of the materials being sought.” Id. The “mere hope that some exculpatory material might turn up” is insufficient. United States v. Cuthbertson, 630 F.2d 139, 146 (3d Cir.1980).

Here, the defendant asserts that the government’s ease is based on a “discredited assumption that there was a relationship between an unusual number of methadone-related overdose deaths in the Portland area during 2002 and CAP Quality. Care, a methadone treatment clinic in Portland [sic] where Dr. Shinderman ... acted as a consultant.” Motion at 2. The motion does not specify by whom or when the assumption was “discredited.” It offers no verifiable evidentiary support for its assertion that “federal law enforcement authorities considered Dr. Shinderman to be the national icon of high-dose methadone treatment and that his prosecution would be a symbolic solution to the methadone overdose deaths.” Id.

More helpfully, the motion asserts that Dr.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Pereira
353 F. Supp. 3d 158 (U.S. District Court, 2019)
United States v. Castro-Ward
385 F. Supp. 3d 156 (U.S. District Court, 2018)
United States v. Cartagena-Albaladejo
299 F. Supp. 3d 378 (U.S. District Court, 2018)
United States v. Sellers
275 F.R.D. 620 (D. Nevada, 2011)

Cite This Page — Counsel Stack

Bluebook (online)
232 F.R.D. 147, 2005 U.S. Dist. LEXIS 25613, 2005 WL 2847379, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-shinderman-med-2005.